TransMedics officer granted RSUs and options

TransMedics Group, Inc. officer Nicholas Corcoran reported equity compensation awards.

Rhea-AI Filing Summary

TransMedics Group, Inc. officer Nicholas Corcoran reported equity compensation awards. He received 11,727 restricted stock units (RSUs), each representing a contingent right to one share of common stock, bringing his direct common stock holdings to 41,558 shares.

He was also granted a stock option for 17,784 shares of common stock at an exercise price of $71.23 per share, expiring on July 10, 2036. The option vests at 2.0833% per month starting after April 10, 2026 and is scheduled to be fully vested by April 10, 2030, subject to continued service.

Insider Trade Summary

Grant/Award: 29,511 shares

Grant/Award 2 txns

Insider Corcoran Nicholas

Role See remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F2	17,784	$0.00	$0.00
Grant/Award	Common Stock F1	11,727	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 17,784 contracts (Direct); Common Stock — 41,558 shares (Direct)

Footnotes (2)

1. F1. Consists of 11,727 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
2. F2. The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service.

Key Figures

RSUs Granted: 11,727 RSUs Option Shares Granted: 17,784 shares Option Exercise Price: $71.23 per share +3 more

6 metrics

RSUs Granted 11,727 RSUs Restricted stock units granted to Nicholas Corcoran on July 10, 2026

Option Shares Granted 17,784 shares Stock option (right to buy) granted to Nicholas Corcoran

Option Exercise Price $71.23 per share Conversion or exercise price of the stock option

Option Expiration July 10, 2036 Expiration date of the granted stock option

Post-Grant Common Holdings 41,558 shares Total common stock held directly after RSU grant

Option Vesting Rate 2.0833% per month Monthly vesting rate from after April 10, 2026 to April 10, 2030

Key Terms

restricted stock units, RSUs, Stock Option (Right to Buy), vesting

4 terms

restricted stock units financial

"Consists of 11,727 restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Consists of 11,727 restricted stock units ("RSUs"). Each RSU represents a contingent right"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with 17,784.0000 shares and a $71.2300 exercise price"

vesting financial

"The option vests at a rate of 2.0833% of the total number of shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Nicholas Corcoran report in the Form 4 for TMDX?

Nicholas Corcoran reported 11,727 RSUs and a stock option for 17,784 shares of TransMedics Group, Inc. common stock, both granted as equity compensation on July 10, 2026.

How many RSUs did Nicholas Corcoran receive from TransMedics Group (TMDX)?

He received 11,727 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of TransMedics Group, Inc. common stock, subject to the applicable vesting and service conditions.

What are the key terms of Nicholas Corcoran’s stock option from TMDX?

The stock option covers 17,784 shares at an exercise price of $71.23 per share, expiring on July 10, 2036, providing a long-dated right to purchase TransMedics common stock if vesting conditions are met.

What is the vesting schedule for Nicholas Corcoran’s TransMedics stock option?

The option vests at 2.0833% per month of the total shares starting after April 10, 2026 and is expected to be fully vested by April 10, 2030, conditioned on continued service.

How many TransMedics (TMDX) shares does Nicholas Corcoran hold after these awards?

Following the RSU grant, Nicholas Corcoran directly holds 41,558 shares of TransMedics Group, Inc. common stock, plus a newly granted option over 17,784 additional shares that remains unexercised.

Do Nicholas Corcoran’s RSUs in TMDX provide immediate common stock?

No. The 11,727 RSUs represent a contingent right to receive one share of TransMedics common stock per unit, typically delivered as the RSUs vest over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/14/2026 - 09:37 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corcoran Nicholas

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MASSACHUSETTS 01810

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		A(1)		11,727	A	$0	41,558	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$71.23	07/10/2026		A		17,784		(2)	07/10/2036	Common Stock	17,784	$0	17,784	D

Explanation of Responses:

1. Consists of 11,727 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service.

Remarks:

SVP of Supply Chain and Operations

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)